We are excited to share that our firm represented Alcon Pharmaceuticals, the renowned Swiss-American pharmaceutical and medical device company, in a major transaction in the field of biomed.
Alcon has acquired Belkin Vision, an innovative Israeli biomed company that has developed a cutting-edge laser device for treating glaucoma. The acquisition was for a total upfront consideration of $81 million, including a cash payment of approximately $65 million, and the potential for up to $385 million in payments, contingent upon Belkin meeting rigorous sales targets.
Partner Ezra Gross led the representation on Alcon, with crucial support from Nataly Margalit, Tali Salzman and Itamar Brown. Ofir Levy, Ofir Paz and Elizabeth Krishmarov Chanan handled all tax related matters, Neta Goshen Brami managed employment integration, Eli Greenbaum advised on IP and Miriam Friedmann handled IIA and other grants. Lihi Katzenelson and Maayan Rublin Malka were in charge of trademarks, Derora Tropp oversaw privacy matters, and Shai Bakal and Chen Lanir handled the competition aspects of the acquisition. Additional thanks to Tamar Tavory and Michael Portman who advised on clinical trials and options respectively and intern Nimrod Tal who conducted due diligence.
